0001209191-19-004530.txt : 20190118 0001209191-19-004530.hdr.sgml : 20190118 20190118160351 ACCESSION NUMBER: 0001209191-19-004530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190116 FILED AS OF DATE: 20190118 DATE AS OF CHANGE: 20190118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gregory Philip D CENTRAL INDEX KEY: 0001343543 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 19533310 MAIL ADDRESS: STREET 1: POINT RICHMOND TECH CENTER II STREET 2: 501 CANAL BOULEVARD SUITE A100 CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-16 0 0001293971 bluebird bio, Inc. BLUE 0001343543 Gregory Philip D C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2019-01-16 4 M 0 1400 75.60 A 28742 D Common Stock 2019-01-16 4 S 0 1900 124.2469 D 26842 D Stock Option (right to buy) 75.60 2019-01-16 4 M 0 1400 0.00 D 2027-02-01 Common Stock 1400 29900 D The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on July 2, 2018. The range in prices for the transaction reported on this line was $124.03 to $124.60. The average weighted price was $124.2469. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2018 and in 36 equal monthly installments thereafter. /s/ Jason F. Cole, Attorney-in-Fact 2019-01-18